Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganovo + Ritonavir for COVID-19
NCT04291729Phase 4Completed
- Sponsor
- Nanchang Ninth Hospital
- Start
- Feb 2020
- Primary completion
- Mar 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of danoprevir in coronavirus disease 2019 (COVID-19), sponsored by Nanchang Ninth Hospital. Primary endpoint: Rate of composite adverse outcomes at 14 days. Started Feb 2020; status: completed.
02
Drugs
danoprevir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04291729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04291729.